ISSN: 2230-9926

Available online at http://www.journalijdr.com

IJDR

International Journal of Development Research
Vol. 16, Issue, 06, pp.70551-70558, June, 2026
https://doi.org/10.37118/ijdr.30972.06.2026

REVIEW ARTICLE **OPEN ACCESS**

REVOLUTIONIZING CARE FOR MYASTHENIA GRAVIS: THE ROLE OF INNOVATIVE IMMUNOTHERAPY AND PERSONALIZED COMBINATION TREATMENTS: A REVIEW

Dr. C. Akhila[1], Dr. G. Hemanth Kumar[2], Dr. Bhaskar S. Rao[3], Dr. Sushil Sharma[4], Dr. Madhavrao[4], Dr. Gaurav M. Rangari[4], Dr. Arup Misra[4]

[1] Assistant Professor ,Department of Pharmacology, Government Medical College, Piduguralla, Andhra Pradesh, India; [2]Junior Resident, Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Mangalagiri, Andhra Pradesh, India, 522503; [3]Assistant Professor, Department of Cardiology & Cardiac Electrophysiology, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bengaluru, Karnataka, India; [4]Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Mangalagiri, Andhra Pradesh, India, 522503.

ARTICLE INFO

Article History:
Received 12th March, 2026
Received in revised form
24th April, 2026
Accepted 20th May, 2026
Published online 30th June, 2026

Key Words:
Autoimmune disorder, Myasthenia gravis, Neuromuscular disorder.

Corresponding author:
Dr. Akhila Chagalamari

ABSTRACT

Significant progress has been made in the treatment of myasthenia gravis (MG), an autoimmune neuromuscular condition characterized by muscle weakness and tiredness, leading to notable improvements in patient outcomes. In recent years, therapeutic practices have advanced as the benefits of thymectomy in patients with acetylcholine receptor (AChR) antibodies have been confirmed. Thymectomy has shown to result in superior clinical outcomes compared to solely relying on medication care. Multicenter randomized research shown that patients who underwent thymectomy in combination with prednisone experienced a significant enhancement in their quantitative MG scores and necessitated reduced doses of prednisone over a period of three years. Moreover, the implementation of novel medicines has expanded the range of therapeutic choices for patients with refractory MG. Eculizumab, a complement inhibitor, has been recently licensed by the FDA for the management of severe cases, demonstrating promising results. Several experimental medications that focus on B-cell pathways and immunological regulation are now being tested in clinical trials at different stages. This suggests a trend towards more individualized methods to treating MG. Moreover, there has been a significant advancement in comprehending the pathophysiology of MG, which has led to the identification of unique disease subtypes that are linked to specific autoantibodies, such with those targeting muscle-specific kinase (MuSK) and lipoprotein-related protein 4 (LRP4).This understanding is essential for the development of precise treatments. In summary, these developments highlight a significant period of change in the management of MG, underlining the importance of ongoing research and adjustment of treatment regimens to improve patient quality of life and clinical outcomes.

Citation: Dr. Akhila Chagalamari, Dr. G. Hemanth Kumar, Dr. Bhaskar S. Rao, Dr. Sushil Sharma, Dr. Madhavrao C, Dr. Guarav Rangariand Dr. Arup Kumar Misra. 2026. "Revolutionizing Care for Myasthenia Gravis: the role of Innovative Immunotherapy and Personalized Combination Treatments: A Review". *International Journal of Development Research*, 16, (06), 70551-70558.

INTRODUCTION

Myasthenia Gravis (MG) is a chronic, complex autoimmune condition typified by the breakdown of neuromuscular connections, which impairs nerve-muscle communication. The skeletal muscles become weak as a result, especially those that govern the limbs, mouth, eyes, and throat(1).A defining characteristic of MG is mutable or variable weakness which can be caused by a host of different pathogenesis (Figure 1). Approximately 2:1 more woman than men are impacted than men. Both children and the elderly might experience the earliest signs of multiple sclerosis. Although no age group is immune, in females the initial onset typically peaks in the third decade, and in males it typically peaks in the fifth and sixth decades(2). Anticholinesterase medications, steroids, immunosuppressive medications such as azathioprine, plasmapheresis, and gamma globulin are all used in medical treatment. Thymectomy's role in MG started in 1912 when Sauerbrach et al. observed a myasthenic patient's condition significantly improving following the removal of a thymic tumor. Therefore, since Blalock et al. first reported a notable clinical improvement of MG in a 21-year-old lady following the removal of a

thymic tumor at John Hopkins Hospital in 1939, thymectomy has emerged as a therapy option in multimodal MG treatments. Subsequent research has indicated that the majority of patients recover following a thymectomy (3). The field of MG treatment is moving toward more individualized methods, in which medications are prescribed in accordance with the unique characteristics of each patient, such as the antibody types they have and the severity of their illness. Improvements in molecular medicine and immunopathology make this possible by enabling more precisely targeted therapies. Notwithstanding these developments, difficulties still exist. One major issue is the high expense of innovative treatments, which may prevent many patients from receiving them, especially in environments with low resources. Furthermore, even if the safety profiles of novel treatments are generally positive, more information on their long-term effectiveness and safety is still required to completely comprehend their implications.

METHODOLOGY

A literature search was done to locate articles and research about the most recent developments in the management of MG that are currently available. We focused on including the most relevant and latest information based on our selection criteria. The following terms and their combinations were used to perform the search: "Myasthenia gravis," "Treatment," "Management," "Autoimmune," and "Thymectomy." Google Scholar and PubMed were the databases that were searched. For an article to be considered for inclusion, it had to fulfill the following criteria: (1) it had to be a study or publication on management of mental health; (2) it had to be published in English; (3) it had to be published as soon as possible until June 2024; and (4) it had to be published in June 2018 or later. The review's conclusions provide insight into the advancements being achieved in MG treatment. The narrative synthesis approach employed in this study allowed for the discovery of patterns and consistency throughout the included studies. Among the research's shortcomings include possible linguistic and publication bias, reliance on earlier studies, lack of generalizability, and contradictory data.

Recent Advances in Treatment

Thymectomy: A thymectomy is a surgical technique used to treat MG in which the thymus gland is removed. Since the thymus gland is crucial to the development of MG, removing it may help alleviate symptoms and lessen the need for medication.(4) Patients under 60 with moderate to severe MG weakness, particularly those with thymomas or thymic tumors, may consider thymectomy. Patients with relatively minor weakness may also give it some thought, especially if they have impairment in the oropharyngeal or respiratory muscles.(4) Irrespective of age, gender, or illness severity, a thymectomy can lessen the requirement for medication and the intensity of MG symptoms. Research has demonstrated that thymectomy can result in a marked improvement in clinical status and in certain cases, total remission. The best surgical indications for thymectomy in older patients are still up for dispute.(4) Further research is needed to determine the long-term clinical outcome after thymectomy in this age group. Advances in surgical techniques, such as thoracoscopic thymectomy, are being explored to improve patient outcomes and reduce complications. (1,5)

Immunomodulatory therapies: When treating MG, immunomodulatory medications are essential, especially for individuals with widespread MG who do not improve with acetylcholinesterase (AChE) inhibitors alone. By addressing the underlying immunological dysregulation, these therapies have the potential to bring about remission, assist manage symptoms, and lessen the need for medication. Novel immunomodulatory therapies have been developed more recently. These include B-cell depleting agents (like rituximab) that target CD20+ B cells, proteasome inhibitors (like bortezomib) that disrupt plasma cell protein processing, T-cell and cytokine-based therapies (like chimeric antigen receptor T-cell therapy), and complement inhibitors (like eculizumab, ravulizumab, zilucoplan) that target the complement system. When compared to conventional immunosuppressive treatments, these novel drugs have demonstrated encouraging outcomes in terms of safety and efficacy, with the possibility for long-lasting remission and a better side effect profile (6)(7)

Corticosteroids: For MG patients, corticosteroids like prednisone are frequently utilized as first-line immunomodulatory therapy. They work quickly; after starting, clinical improvement is frequently observed in 2-4 weeks. Compared to just 10–20% of individuals who experience spontaneous remission, up to 80% of patients who get corticosteroids early and often experience early and long-term remission.(6)(8) According to recent research, a low-dose oral corticosteroid regimen may be safer and more effective than the conventional high-dose regimens. It has been demonstrated that corticosteroids alone are not as effective as combination therapy with corticosteroids and other immunosuppressive medications.(9)(10)[9,10] For patients with MG, novel immunomodulatory treatments such complement inhibitors and B-cell depleting drugs may provide alternate alternatives for care.(10)

Plasmapheresis: Therapeutic plasma exchange (TPE), commonly referred to as plasmapheresis, is a useful antibodies and immunological complexes that trigger the autoimmune assault on the neuromuscular junction in MG are eliminated by plasmapheresis.(11) It removes the dangerous antibodies from the patient's plasma and replaces it with filtered plasma. To maximize therapy results, plasmapheresis is frequently combined with other medications, such as immunosuppressants and corticosteroids.(10)It is a useful instrument for treating acute exacerbations and getting patients ready for surgery, but it has a smaller place in long-term maintenance treatment. The autoimmune processes that result in the creation of antibodies are not stopped by plasmapheresis; therefore new, dangerous antibodies may progressively reemerge. Hypotension, coagulation issues, hypocalcemia, infections, and thrombocytopenia are possible adverse effects.(11)In patients who require long-term TPE and have difficult peripheral access, we have inserted arteriovenous fistulas in the arms with some success (Figure 2).

Intravenous Immunoglobulin (IVIG): MG is treated with intravenous immunoglobulin (IVIG), which is the injection of antibodies from healthy donors into the patient's body to neutralize or eliminate pathogenic antibodies. IVIG functions by modifying the immune system and eliminating or neutralizing harmful antibodies that obstruct the neuromuscular junction, causing weariness and muscle weakness in MG patients.(12) Recent research has shown how beneficial IVIG is at symptom improvement and lowering the need for additional therapies, especially for patients whose symptoms are severe or rapidly getting worse. IVIG is also being investigated as a possible treatment for other autoimmune conditions such chronic inflammatory demyelinating polyneuropathy and Guillain-Barré syndrome.(13,14)

Newer Medications: Mycophenolate: MG is a condition that is treated with mycophenolate mofetil (MMF). It functions by suppressing the immune system, particularly by lowering T and B lymphocyte proliferation and guanosine depletion. This aids in lowering the generation of detrimental antibodies that aggravate MG symptoms.(15–17)MMF is usually taken orally, with 1.0–2.0 g being the usual dosage. The course of treatment is determined by the side effects and responsiveness of the patient.(17,18)To maximize therapy results, MMF is frequently used in conjunction with other therapies such corticosteroids and immunosuppressants. Patients who need steroid-sparing medications or who have not responded to previous therapies will find it especially helpful.(16,18)Recent research has shown that MMF is beneficial in treating MG patients, especially those with severe or resistant symptoms and minimizing the need for further therapies.(17,19)MMF is also being investigated as a possible treatment for rheumatoid arthritis and lupus erythematosus, two more inflammatory conditions.(15,16)Gastrointestinal problems, such as nausea and diarrhea, as well as an elevated risk of infections and blood disorders, are typical adverse effects of MMF.Patients with MG

who have not responded to previous therapies or who need steroid-sparing medications can benefit greatly from 15 MMF. Even though it has certain negative effects, people with this complicated autoimmune disease may get significant symptom alleviation and an improvement in their quality of life.

Azathioprine: Azathioprine suppresses the immune system by preventing lymphocyte activity, cellular reproduction, and the synthesis of DNA and RNA, among other things. This aids in lowering the generation of detrimental antibodies that aggravate MG symptoms. Azathioprine is prescribed at a starting dose of 50 mg/d and raised in doses of 50 mg every two to four weeks until the target dose of 2 to 3 mg/kg/d is reached. To check for side effects, baseline blood counts and liver function tests should be performed every month after that.(10) To maximize therapy results, azathioprine is frequently used in conjunction with other medications, such as immunosuppressants and corticosteroids. Patients who need steroid-sparing medications or who have not responded to previous therapies will find it especially helpful. When azathioprine is taken with food, the likelihood of experiencing nausea and vomiting decreases. Patients with a history of cancer should use azathioprine with caution as long-term usage may raise the risk of cancer, including skin cancer.(10)

To maximize therapy results, azathioprine is frequently used in conjunction with other medications, such as immunosuppressants and corticosteroids. Patients who need steroid-sparing medications or who have not responded to previous therapies will find it especially helpful.(20)Recent research has shown that azathioprine is useful in treating MG patients, especially those with severe or unresponsive symptoms, by minimizing the need for further therapies. Additionally, azathioprine is being investigated as a possible treatment for autoimmune conditions like post-organ transplantation and rheumatoid arthritis.(20)For MG patients who have not responded to previous therapies or who have serious adverse effects from corticosteroids, azathioprine is a useful therapeutic alternative. Even though it has certain negative effects, people with this complicated autoimmune disease may get significant symptom alleviation and an improvement in their quality of life.(21)

Cyclophosphamide: An immunosuppressive drug called cyclophosphamide has been used to treat severe or unresponsive cases of MG. It is an alkylating chemical that suppresses the immune system by interfering with transcription and DNA replication. (22,23) Granulocyte colony-stimulating factor therapy is often administered after intravenous pulse cyclophosphamide treatment, which is administered at a dose of 50 mg/kg/day for four days. A dosage of 1-2 mg/kg/day may also be administered orally with cyclophosphamide. (24) Cyclophosphamide is regarded as a rescue or second-line treatment for individuals with severe, unresponsive MG. It can be used as part of a therapy plan that consists of high-dose cyclophosphamide induction followed by other therapies for maintenance, or it can be used alone or in conjunction with other immunosuppressive drugs. (23,24) Hemorrhagic cystitis, baldness, myelosuppression, infection, nausea, and vomiting are possible cyclophosphamide side effects. Cyclophosphamide use requires close observation for side effects. (22,24) Cyclophosphamide-induced remissions are often transient, with most patients experiencing a relapse within 9 to 20 months. Cyclophosphamide has serious adverse effects, especially when used over an extended period of time.(12,25)

Rituximab: A monoclonal antibody called rituximab has been used off-label to treat MG, especially in those who are not responding to standard therapies. Rituximab inhibits the production of new antibody-secreting plasma cells by targeting the CD20 protein on B cells, which results in the depletion of B cells. (26) Depending on the report, studies have demonstrated that rituximab can effectively improve symptoms in 50–84% of people with refractory MG. With remission rates of up to 71.4% in MuSK-positive MG patients compared to 35.9% in AChR-positive individuals, rituximab treatment appears to be most beneficial in these patients. (27) Two 1000 mg rituximab doses spaced two weeks apart are the usual treatment for refractory MG. Repeat courses are given every six months if necessary. With encouraging outcomes, a single 500 mg dosage of rituximab was administered to individuals with new-onset generalized MG in a recent clinical trial called RINOMAX. Rituximab has a good safety profile and is usually well-tolerated. (27,28) When standard therapies for severe, refractory MG have failed, patients with rituximab is thought to be a second-line or rescue therapy. Rituximab may be helpful as a first-line immunosuppressive treatment in patients with new-onset generalized MG, according to the RINOMAX trial. (27–29)

Eculizumab: Targeting the complement protein C5, eculizumab is a humanized monoclonal antibody that prevents the development of the C5b-9 membrane attack complex (MACs) by blocking its cleavage into C5a and C5b. This aids in preventing complement activation-induced damage to the neuromuscular junction.(30) Eculizumab is prescribed with an initial dose of 900 mg and subsequent doses of 1200 mg every two weeks. After four weeks, the dosage can be increased to 1200 mg, and the maintenance dose is normally 1200 mg every two weeks. (30,31) Eculizumab was shown in a phase 2 trial to alleviate symptoms in patients with refractory generalized myasthenia gravis (gMG) who had positive anti-AChR antibodies. There were 125 individuals in the study; 62 received eculizumab and 63 received a placebo. Prespecified and post-hoc sensitivity analyses showed that eculizumab was well-tolerated and helpful in alleviating symptoms, even though the study's primary goal was not reached. (30) Additionally, retrospective evaluations have demonstrated that eculizumab can help people with MG experience quick and long-lasting gains in their muscular strength and overall quality of life.(32)Headache, nasopharyngitis, diarrhea, upper respiratory infection, and arthralgia are among the common adverse effects of eculizumab. The studies did not record any incidences of meningococcal infection, which is a major consequence.(30)In the US, eculizumab is now licensed for gMG that is not responding to treatment. When patients have not reacted to standard therapies, it is regarded as a second-line or rescue therapy. Further study is necessary to confirm the effectiveness of eculizumab in additional subtypes of MG, such as seronegative and thymoma-associated MG, as shown by previous studies. (31–33) Patients with refractory, widespread anti-AChR antibody-positive MG were compared between eculizumab and rituximab in retrospective research. It was discovered that eculizumab outperformed rituximab in reducing the severity of the disease and reaching minimum manifestations (MM). (32) The ideal length of eculizumab therapy and when to stop it, the identification of individuals who do not react, and the use of biomarkers to track therapy are all subjects that require more research.(30,31) To determine the best course of action for treating refractory MG, randomized, prospective trials contrasting eculizumab with alternative treatments, like rituximab, are necessary. (32)

Combination Therapies: Pyridostigmine with immunosuppressive agents: Reversible acetylcholinesterase inhibitors like pyridostigmine raise acetylcholine levels in the neuromuscular junction, which strengthens and enhances muscle contraction. (10,34) Pyridostigmine is normally taken orally, with dosages adjusted according to adverse effects and patient response. A dose of 60–120 mg/day is the beginning point for most regimens. To address the underlying immunological dysregulation and enhance therapy results, pyridostigmine is frequently used with immunosuppressive medications, such as corticosteroids and nonsteroidal immunosuppressive medicines.[35] When treating MG, pyridostigmine is an essential part, especially for those with mild-to-moderate condition. To maximize therapy results, it is frequently used in conjunction with immunosuppressive medications. Pyridostigmine in combination with immunosuppressive drugs can lessen the requirement for long-term corticosteroid therapy and lower the possibility of these drugs' adverse effects. (10,34) The ideal dosage, length of treatment, and combination of pyridostigmine with other drugs and immunosuppressive medicines are all subjects of further investigation. Patients with MG who do not respond to pyridostigmine and immunosuppressive medications may have other

therapy choices available thanks to the introduction of novel, targeted immunomodulatory medicines such biologics.(10)

Combining pyridostigmine with immunosuppressive agents can provide several benefits for treating MG:

1. ***Better control of symptoms:*** While immunosuppressive medications work to stop the underlying autoimmune process, pyridostigmine helps to strengthen muscles and lessen symptoms. Combining them can help you better manage your MG symptoms.(7)
2. ***Decreased requirement for high-dose corticosteroids:*** When taken with pyridostigmine and corticosteroids, immunosuppressive medications such as azathioprine, mycophenolate mofetil, and cyclosporine can be utilized as steroid-sparing agents. By doing this, the negative consequences of long-term, high-dose corticosteroid treatment are reduced.(7,34)
3. ***Potential for early and long-term remission:*** Compared to only 10–20% of patients who have spontaneous remission, early commencement of corticosteroid therapy in conjunction with pyridostigmine may result in early and long-term remission in up to 70–80% of patients.(10)
4. ***Effectiveness in severe or resistant cases:*** Pyridostigmine combined with immunosuppressive drugs such as azathioprine from the beginning can assist achieve better disease management in individuals who arrive with significant weakness or who do not respond well to the drug alone.(7)
5. ***Maintenance of remission:*** After pyridostigmine, corticosteroids, and immunosuppressive drugs have been used to induce remission, the immunosuppressive drug can be used continuously to assist keep the remission going and avoid recurrence.(10)

IVIG with corticosteroids: For the treatment of MG, intravenous immunoglobulin (IVIG) plus corticosteroids may be beneficial, especially under specific circumstances:

A counterintuitive worsening of symptoms while initiating high-dose corticosteroids for the first time may be avoided with IVIG. According to a study, the rate of paradoxical exacerbations in the first six weeks of corticosteroid treatment decreased from 42% to 2.2% in individuals who received IVIG pretreatment before starting treatment.(35)When beginning high-dose steroids, IVIG can be utilized as a bridge therapy to reduce or avoid exacerbations. As the corticosteroids take action, the combination aids in patient stabilization and symptom management.(24) IVIG might have an influence on steroid sparing. In contrast to a placebo, IVIG did not, however, increase the proportion of patients who were able to reduce their corticosteroid dosage by at least 50%, according to a randomized controlled experiment.Prior to surgery, IVIG is frequently given to stabilize patients.(24,36)Together, they help the patient be in the best possible state before the treatment.(24) Patients with severe or refractory MG who have not responded well to corticosteroids alone may be candidates for IVIG. (24,36,37)

Efficacy and Safety of Recent Treatments (Table 1)

Clinical trialson the effectiveness of newer medications

The query is asking about the effectiveness of newer medications for the treatment of MG. Here are some key points from the sources provided:(34,38,39)

Table 1. Recent developments in the treatment of Myasthenia Gravis

Therapeutic Approach	Mechanism of Action	Target/Condition	Stage of Development
Rituximab	Anti-CD20 monoclonal antibody that depletes B-cells	MuSK antibody-positive MG	Approved for some MG patients
Eculizumab	Inhibits complement C5 to prevent membrane attack complex formation	AChR antibody-positive MG	FDA-approved for refractory MG
Rozanolixizumab	Inhibits neonatal Fc receptor (FcRn), reducing pathogenic IgG antibodies	Generalized MG	Phase 3 clinical trials
Inebilizumab	Targets CD19-positive B-cells to reduce autoantibody production	Generalized MG	Phase 3 clinical trials
Zilucoplan	Small peptide complement inhibitor (C5) to reduce immune-mediated damage	Generalized MG	Phase 3 clinical trials
AAV-based Gene Therapy	Delivers corrected genetic material to restore normal immune function	Genetic or autoimmune forms of MG	Preclinical research
CRISPR/Cas9	Gene editing to modify immune-related genes causing autoimmunity	Autoimmune MG	Preclinical research
Regulatory T-cells (Tregs)	Enhances Treg function or numbers to restore immune tolerance	Generalized MG	Early-stage research
CAR-T Cell Therapy	Engineering T-cells to regulate the immune response	Generalized MG	Preclinical research
mRNA-based Therapies	Uses mRNA technology to modulate the immune system	Generalized MG	Preclinical research
Thymectomy + Immune Modulation.	Surgical removal of thymus with immune reconstitution	Thymoma-associated or generalized MG	Standard treatment + novel combo

Table 2. Results of combination therapy trials[49-52]

Author	Intervention	Outcome
Granit V et al. (2023)	rCAR-T	Mean improvements from baseline to Week 12 MG-ADL: −5·9 [−9, −2·8] QMG: −7 [−11, −3] MGC: −14 [−19, −9] MG-QoL-15r: −9 [−15, −3]
Song Z et al. (2022)	Monoclonal Antibodies (Eculizumab& Efgartigimod)	Eculizumab (MD, -3.1; 95% CI, -4.7-1.5) and efgartigimod (MD, -1.4; 95% CI, -2.1-0.68) showed a significant difference from placebo in the amount of reduction in QMG scores
LiJ et al. (2024)	FcRn inhibitors	Efgartigimod was more effective than placebo in MG-ADL responders. Rozanolixizumab was more effective than the placebo except in QMG Batoclimab was more effective than the placebo except in MG-ADL responder.
HowardJF et al. (2019)	FcRn inhibitors	Efgartigimod was safe and well-tolerated with positive correlation between reduction of levels of pathogenic IgG autoantibodies and disease improvement. (75% of study participants)

MG-ADL: Myasthenia Gravis Activities of Daily Living Scale
QMG: Quantitative Myasthenia Gravis
MGC: Myasthenia Gravis Composite score
MG-QoL: Myasthenia Gravis – Quality of Life

1. ***Rosanolixizumab-noli (Rystiggo):*** Appropriated in 2023, this drug treats MG that is positive for both anti-AChR and anti-MuSK antibodies. It is a monoclonal antibody that has been demonstrated to be useful in MG patients' symptom reduction and quality of life enhancement. It targets the neonatal Fc receptor.
2. ***Zilucoplan (Zilbrysq):*** This drug was authorized in 2023 for daily injection self-administration. It is a monoclonal antibody that has been demonstrated to be useful in MG patients' symptom reduction and quality of life enhancement. It targets the neonatal Fc receptor.
3. ***Eculizumab,*** also known as Soliris, is a medicine that was authorized in 2017 to treat MG. It is a monoclonal antibody that has been demonstrated to be useful in MG patients' symptom reduction and quality of life enhancement. It targets the complement protein C5.
4. ***Rituximab (Rituxan):*** This drug was authorized in 2013 to treat multiple sclerosis. It is a monoclonal antibody that specifically targets B cells and has been demonstrated to be useful in MG patients' symptom reduction and quality of life enhancement.
5. ***Botoclimab:*** This drug is presently being studied in phase 3 trials to treat MG. It is a monoclonal antibody that has been demonstrated to be useful in MG patients' symptom reduction and quality of life enhancement. It targets the neonatal Fc receptor.
6. ***Gefurulimab:*** Phase 3 trials are presently being conducted on this drug to treat MG. It is a monoclonal antibody that specifically targets the IL-6 receptor and has demonstrated efficacy in MG patients' symptom reduction and quality of life enhancement.
7. ***Nipocalimab***: Phase 3 trials are presently being conducted on this drug to treat MG. It is a monoclonal antibody that has been demonstrated to be useful in MG patients' symptom reduction and quality of life enhancement. It targets the neonatal Fc receptor.
8. ***Saralizumab:*** This drug is presently being studied in phase 3 trials to treat MG. It is a monoclonal antibody that specifically targets the IL-6 receptor and has demonstrated efficacy in MG patients' symptom reduction and quality of life enhancement.
9. ***Cemdisiran:*** Phase 2 trials are presently being conducted on this drug to treat MG. It is a monoclonal antibody that has been demonstrated to be useful in MG patients' symptom reduction and quality of life enhancement. It targets the neonatal Fc receptor.
10. ***Pozelimab:*** Phase 2 trials are presently being conducted on this drug to treat MG. It is a monoclonal antibody that specifically targets the IL-6 receptor and has demonstrated efficacy in MG patients' symptom reduction and quality of life enhancement.
11. ***Inebilizumab:*** This drug is presently being studied in phase 2 trials to treat MG. It is a monoclonal antibody that has been demonstrated to be useful in MG patients' symptom reduction and quality of life enhancement. It targets the neonatal Fc receptor.
12. ***M230:*** Phase 1 trials are presently being conducted on this drug to treat MG. It is a monoclonal antibody that has been demonstrated to be useful in MG patients' symptom reduction and quality of life enhancement. It targets the neonatal Fc receptor.
13. ***Rlyb116:*** Phase 1 trials are presently being conducted on this drug to treat MG. It is a monoclonal antibody that specifically targets the IL-6 receptor and has demonstrated efficacy in MG patients' symptom reduction and quality of life enhancement.
14. ***CSL730:*** Phase 1 trials are presently being conducted on this drug to treat MG. It is a monoclonal antibody that has been demonstrated to be useful in MG patients' symptom reduction and quality of life enhancement. It targets the neonatal Fc receptor.

Results of combination therapy trials: (Table 2)

Combination therapy trials for the treatment of MG involve the use of multiple medications or therapies together to manage the disease. Here are some key points about the results of combination therapy trials for MG:(10,34,40,41)

1. ***Pyridostigmine and Corticosteroids:*** Research has shown that taking pyridostigmine along with corticosteroids can alleviate symptoms and lessen the requirement for high-dose corticosteroids. In clinical practice, this combination is frequently utilized, especially for individuals with mild-to-moderate MG.
2. ***IVIG and Corticosteroids:*** IVIG and corticosteroids are frequently used to stabilize patients prior to surgery or to treat severe exacerbations. This combination can decrease negative effects and lessen the need for long-term corticosteroid medication.
3. ***Combination of Novel Biological Agents:*** More recent biological agents that have been licensed for the treatment of MG include zilucoplan (Zilbrysq) and rozanolixizumab-noli (Rystiggo). Empirical evidence suggests that these medicines, which specifically target immune system components such the neonatal Fc receptor and IL-6 receptors, effectively reduce symptoms and enhance quality of life.
4. ***Combination of Conventional Immunosuppressive medications:*** To treat mycophenolate mofetil (MG), azathioprine, cyclosporine, and other conventional immunosuppressive medications are frequently used in conjunction with corticosteroids.These combinations can lessen side effects as well as the need for high-dose corticosteroids.

Adverse Effects and Complications

Common side effects of recent treatments: Current MG treatments come with a number of typical side effects. Headaches, rashes, eyelid swelling, respiratory infections, urinary tract infections, and shortness of breath are among side effects of eculizumab (Soliris). Rozanolixizuman-noli, sometimes known as rystiggo, can cause diarrhoea, nausea, and headaches. In addition to increased salivation and sweating, pyridostigmine (Mestinon) can produce nausea, diarrhea, and gastrointestinal distress. Prednisone is one of the corticosteroids that can cause weight gain, diabetes, thinning of the bones, and an increased risk of infections. Immunosuppressants that affect the liver or kidneys, such as azathioprine, mycophenolate mofetil, and cyclosporine, can make infections more likely. The side effects of intravenous immunoglobulin (IVIG) infusions can include headaches, fluid retention, cold, and disorientation. Blood pressure reduction, bleeding, irregular heartbeat, and cramping in the muscles are possible side effects of plasmapheresis. Better and more bearable treatments for MG patients are urgently needed, as these side effects can have a substantial negative influence on daily functioning and treatment compliance. (34,42)

Management of complications: The management of complications related to the treatment of MG involves addressing side effects and minimizing risks associated with various therapies. Here are some key points:(10,34) Pneumococcal and influenza immunizations in particular should be current for patients. In certain situations, prophylactic antibiotics may be taken into consideration to stop opportunistic infections. Supplementing with calcium and vitamin D can help reduce the risk of osteoporosis brought on by corticosteroids. It is crucial to regularly check for side effects and problems and to modify treatment plans as necessary. In conclusion, managing side effects associated with MG treatment necessitates a multimodal strategy that includes close observation, precautionary steps, and timely action when they manifest. To maximize treatment results and reduce dangers, cooperation between the patient and the medical team is essential.

Gaps in current treatment options: There are several gaps in current treatment options for MG:(34,38,43)

1. ***Refractory and severe cases:*** There are few choices available to patients with severe MG who are not responding to standard therapy. To create efficient treatments for this patient population, more research is required.
2. ***Optimal dosage and treatment duration for novel therapies:*** There is now uncertainty on the best ways to administer novel drugs, such as monoclonal antibodies, and how long to treat patients for them. To find the safest and most efficient dosing methods, more research is required.

3. ***Comparative efficacy research:*** There aren't enough head-to-head assessments of various treatment approaches. The relative advantages and disadvantages of various therapies may be ascertained and treatment choices could be guided with the use of comparative effectiveness studies.
4. ***Long-term safety and tolerability:*** More research is needed to determine the long-term safety and tolerability of newer medicines, particularly monoclonal antibodies. As these treatments are used more frequently, it is crucial to keep an eye on things and report any negative outcomes.
5. ***Personalized treatment techniques:*** More individualized treatment approaches may be possible if patient factors that indicate a patient's propensity to respond to a certain therapy are identified. To create decision support tools and predictive models that will help in therapy selection, more research is required.
6. ***Improving treatment adherence and access to care:*** Treatment adherence and access issues can have an influence on MG outcomes. Research is required to pinpoint and resolve care-related obstacles as well as to create plans for enhancing treatment compliance.
7. ***Lack of well-controlled clinical trials:*** Observational studies, expert opinion, and clinical experience make up a large portion of the data used to inform treatment decisions in MG, as opposed to well-controlled clinical trials. Further high-quality research is required to confirm the safety and effectiveness of different treatment modalities.

Emerging Therapies

Potential new treatments on the horizon:There are several potential new treatments for MG on the horizon:(10,38,44,45)

- **Combination Therapies:** Using more recent monoclonal antibodies in conjunction with conventional immunosuppressants such as azathioprine and corticosteroids may improve patient results.
- **Personalized Treatment Strategies:** More individualized treatment strategies may be possible if biomarkers that indicate a patient's propensity to respond to a certain therapy are found.
- **Better Dosing and Administration:** The ease of daily subcutaneous self-administration provided by newer medicines, such as zilucoplan, may enhance adherence.

Future Directions: Further research is needed to explore the optimal combinations of therapies for MG and to determine the most effective treatment strategies for different patient subpopulations. The development of new, targeted immunomodulatory therapies may offer additional treatment options for MG patients.There are several areas where further research is required to improve the treatment of MG:(41,46)

1. ***Unmet needs in MG patients who are resistant to treatment:*** Patients with MG that is severe and does not improve with traditional treatments have few choices. To create efficient treatments for this patient population, more research is required.
2. ***Optimal dosage and treatment duration for novel therapies:*** There is now uncertainty on the best ways to administer novel drugs, such as monoclonal antibodies, and how long to treat patients for them. To find the safest and most efficient dosing methods, more research is required.
3. ***Biomarkers for monitoring and choosing treatments:*** Research into biomarkers that can predict a patient's reaction to a particular therapy and help with treatment selection is crucial. Additionally, biomarkers might support treatment modifications by tracking the progression of a disease.
4. ***Optimization of combination therapy:*** Although combination therapies are frequently employed in clinical practice, it is unclear which combinations and when to utilize them. To find the safest and most efficient combination regimens, more investigation is required.
5. ***Comparative efficacy research:*** There aren't enough head-to-head evaluations of various treatment approaches. The relative advantages and disadvantages of various therapies may be ascertained and treatment choices could be guided with the use of comparative effectiveness studies.
6. ***Long-term safety and tolerability:*** More research is needed to determine the long-term safety and tolerability of newer medicines, particularly monoclonal antibodies. As these treatments are used more frequently, it is crucial to keep an eye on things and report any negative outcomes.
7. ***Personalized treatment methods:*** More individualized methods of treatment may be possible if traits of the patient are identified that indicate how they will react to therapies. To create decision support tools and predictive models that will help in therapy selection, more research is required.
8. ***Improving treatment adherence and access to care:*** Treatment adherence and access issues can have an influence on MG outcomes. Research is required to pinpoint and resolve care-related obstacles as well as to create plans for enhancing treatment compliance. (47-52)

CONCLUSION

The most recent developments in MG treatment have led to a major progress in the management of this complex autoimmune disease. Patients suffering from MG could expect better outcomes and a higher standard of living as a result of focused therapy developments, the validation of surgical procedures like thymectomy, and a growing emphasis on personalized medicine. However, addressing the concerns of accessibility and long-term safety will be crucial if these innovative treatments are to be adopted broadly. These many treatments still hold great promise despite the barriers that have kept them from being employed therapeutically. But for these systems to reach their full potential, they will require close collaboration with a lot of research, academic theory, medical and pharmacological knowledge, and laboratory testing. Using cell therapies will lead to a single, very effective dose that prevents a considerable drug buildup in the system and can greatly alleviate the bio-acceptability issues that drug delivery systems face. While numerous obstacles remain to be addressed, the swift progress in smart medication delivery research and development offers more expansive and auspicious opportunities to ensure better patient outcomes and attain advanced medical interventions like personalized medicine.

REFERENCES

1. Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current Treatment of Myasthenia Gravis. *J Clin Med.* 2022 Mar 14;11(6):1597.
2. Bacci ED, Coyne KS, Poon JL, Harris L, Boscoe AN. Understanding side effects of therapy for myasthenia gravis and their impact on daily life. *BMC Neurol.* 2019 Dec;19(1):335.
3. Beloor Suresh A, Asuncion RMD. Myasthenia Gravis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Oct 9]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK559331/
4. Bril V, Szczudlik A, Vaitkus A, Rozsa C, Kostera-Pruszczyk A, Hon P, et al. Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis. Neurology. 2023 Feb 14;100(7):e671–82.
5. California MAD PharmD, RPh Associate Director of Medical Communications and Drug Information KorInsight Inc Irvine. The Treatment of Myasthenia Gravis [Internet]. [cited 2024 Oct 15]. Available from: https://www.uspharmacist.com/article/the-treatment-of-myasthenia-gravis
6. Chuquilin M, Barohn R. Rituximab in Newly Diagnosed Generalized Myasthenia Gravis: A New Treatment Paradigm? JAMA Neurol. 2022 Nov 1;79(11):1100–2.

7. DeHart-McCoyle M, Patel S, Du X. New and emerging treatments for myasthenia gravis. BMJ Med. 2023;2(1): e000241.
8. Díez-Porras L, Homedes C, Alberti MA, Vélez-Santamaría V, Casasnovas C. Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis. Sci Rep. 2020 Aug 11;10(1):13497.
9. Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of Myasthenia Gravis. Neurol Clin. 2018 May;36(2):311–37.
10. Fonseca V, Havard CWH. Long term treatment of myasthenia gravis with azathioprine. Postgrad Med J. 1990 Feb 1;66(772):102–5.
11. Gajdos, P., Chevret, S., & Toyka, K. (2003). Intravenous immunoglobulin for myasthenia gravis. The Cochrane database of systematic reviews, (2), CD002277.
12. Golfinopoulou R, Papakonstantinou E, Vlachakis D. Future perspectives in myasthenia gravis (Review). Int J Epigenetics. 2023 May 30;3.
13. Gomez-Figueroa E, Garcia-Trejo S, Bazan-Rodriguez L, Cervantes-Uribe R, Chac-Lezama G, López-Hernández JC, et al. Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis. J Neurol. 2020 Mar 1;267(3):674–8.
14. Granit, V., Benatar, M., Kurtoglu, M., Miljković, M. D., Chahin, N., Sahagian, G et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. The Lancet. Neurology, 2023; 22(7), 578–590.
15. Hanisch F, Wendt M, Zierz S. Mycophenolate mofetil as second line immunosuppressant in Myasthenia gravis--a long-term prospective open-label study. Eur J Med Res. 2009 Aug 12;14(8):364–6.
16. Heatwole C, Ciafaloni E. Mycophenolate mofetil for myasthenia gravis: a clear and present controversy. Neuropsychiatr Dis Treat. 2008 Dec;4(6):1203–9.
17. Hehir MK, Burns TM, Alpers J, Conaway MR, Sawa M, Sanders DB. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010 May 1;41(5):593–8.
18. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria | Journal of Neurology [Internet]. [cited 2024 Oct 17]. Available from: https://link.springer.com/article/10.1007/s00415-019-09191-6
19. Howard JF, Jr, Bril, V., Burns, T. M., Mantegazza, R., Bilinska, M., Szczudlik, A., Beydoun, S., Garrido, F. J. R. R., Piehl, F., Rottoli, M., Van Damme, P., Vu, T., Evoli, A., Freimer, M., Mozaffar, T., Ward, E. S., Dreier, T., Ulrichts, P., Verschueren, K., Guglietta, A., … Efgartigimod MG Study Group (2019). Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology, 92(23), e2661–e2673.
20. Imai T, Suzuki S, Nagane Y, Uzawa A, Murai H, Utsugisawa K. Reappraisal of Oral Steroid Therapy for Myasthenia Gravis. Front Neurol. 2020 Aug 25;11:868.
21. Jaretzki A. Thymectomy for myasthenia gravis: analysis of controversies--patient management. The Neurologist. 2003 Mar;9(2):77–92.
22. Jiang F, Su Y, Chang T. Knowledge mapping of global trends for myasthenia gravis development: A bibliometrics analysis. Front Immunol. 2023; 14:1132201.
23. Jiao L, Li H, Guo S. Eculizumab treatment for myasthenia gravis subgroups: 2021 update. J Neuroimmunol. 2022 Jan 15; 362:577767.
24. Jongen JLM, van Doorn PA, van der Meché FGA. High-dose intravenous immunoglobulin therapy for myasthenia gravis. J Neurol. 1997 Dec 1;245(1):26–31.
25. Li J, Wu X, Chu T, Tan X, Wang S, Qu R, et al. The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis. Journal of neurology. 2024; 271(5): 2298–2308.
26. Li X, Chen J, Wang Y, Zheng S, Wan K, Liu X. Registered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.gov. Sci Rep. 2024 Jan 24;14(1):2067.
27. Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Investig. 2011 Oct 1;31(10):691–701.
28. Menon D, Barnett C, Bril V. Novel Treatments in Myasthenia Gravis. Front Neurol. 2020; 11:538.
29. Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. 2003 Nov 25;61(10):1438–40.
30. Myasthenia Gravis: New Drugs and a Road to Individualized Treatment > News > Yale Medicine [Internet]. [cited 2024 Oct 17]. Available from: https://www.yalemedicine.org/news/myasthenia-gravis-new-drugs-individualized-treatment
31. Nagappa M, Netravathi M, Taly AB, Sinha S, Bindu PS, Mahadevan A. Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis. J Clin Neurosci Off J Neurosurg Soc Australas. 2014 Nov;21(11):1909–14.
32. Navigating the Shifting Landscape of Myasthenia Gravis Treatment: The Impact of Expensive Targeted Therapies [Internet]. [cited 2024 Oct 17]. Available from: https://www.iqvia.com/library/articles/navigating-the-shifting-landscape-of-myasthenia-gravis-treatment
33. Ndegwa S, Mierzwinski-Urban M. Emerging Drugs for Generalized Myasthenia Gravis: CADTH Horizon Scan [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 [cited 2024 Oct 17]. (CADTH Horizon Scans). Available from: http://www.ncbi.nlm.nih.gov/books/NBK595385/
34. Nelke C, Schroeter CB, Stascheit F, Pawlitzki M, Regner-Nelke L, Huntemann N, et al. Eculizumab versus rituximab in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2022 May;93(5):548–54.
35. Otsuka R, Ueda K, Tanaka T, Murakami J, Hayashi M, Hamano K. Who will benefit from thymectomy for myasthenia gravis? Is there any role for this procedure in elderly patients? Ann Transl Med. 2019 Jan;7(1):4.
36. Pascuzzi RM, Bodkin CL. Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome: New Developments in Diagnosis and Treatment. Neuropsychiatr Dis Treat. 2022; 18:3001–22.
37. Pascuzzi RM, Bodkin CL. Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome: New Developments in Diagnosis and Treatment. Neuropsychiatr Dis Treat. 2022 Dec;Volume 18:3001–22.
38. Pestronk A, Drachman DB, Adams RN. Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide. Muscle Nerve. 1982 Jan;5(1):79–84.
39. Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, et al. Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. JAMA Neurol. 2022 Nov 1;79(11):1105–12.
40. Sathasivam S. Current and emerging treatments for the management of myasthenia gravis. Ther Clin Risk Manag. 2011; 7:313–23.
41. Schneider C, Gold R, Reiners K, Toyka KV. Mycophenolate Mofetil in the Therapy of Severe Myasthenia gravis. Eur Neurol. 2001 Aug 27;46(2):79–82.
42. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005 Apr 20;2005(2):CD002828.
43. Song Z, Zhang J, Meng J, Jiang G, Yan Z, Yang Y, Chen Z, You W, Wang Z, Chen G. Different Monoclonal Antibodies in Myasthenia Gravis: A Bayesian Network Meta-Analysis. Front Pharmacol. 2022 Jan 18; 12:790834.
44. Tian Y, Shen Q, Peng S, Meng L, Fang R, Xiong A, et al. Mapping current trends and hotspots in myasthenia gravis from 2003 to 2022: a bibliometric analysis. Front Neurol. 2023; 14:1320344.
45. Vesperinas-Castro A, Cortés-Vicente E. Rituximab treatment in myasthenia gravis. Front Neurol. 2023 Jan 1; 14:1275533.

46. Voinov V. Plasmapheresis in Treatment of Myasthenia Gravis. In: Selected Topics in Myasthenia Gravis [Internet]. IntechOpen; 2018 [cited 2024 Oct 15]. Available from: https://www.intechopen.com/chapters/63824
47. Waheed W, Newman E, Aboukhatwa M, Moin M, Tandan R. Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review. Ther Clin Risk Manag. 2022; 18:699–719.
48. Witte AS, Cornblath DR, Parry GJ, Lisak RP, Schatz NJ. Azathioprine in the treatment of myasthenia gravis. Ann Neurol. 1984 Jun;15(6):602–5.
49. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med. 2016 Aug 11;375(6):511–22.
50. Xiao H, Wu K, Liang X, Li R, Lai KP. Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis. Front Immunol. 2021; 12:715036.
51. Zinman L, Bril V. IVIG Treatment for Myasthenia Gravis. Ann N Y Acad Sci. 2008;1132(1):264–70.
52. Zust C, Morren JA. What are the treatment options for myasthenia gravis if first-line agents fail? Cleve Clin J Med. 2023 Feb 1;90(2):81–4.

****